In the competitive and heavily regulated pharmaceutical industry, scientific and regulatory due diligence is not just a checkbox—it’s a critical process that can make or break mergers, acquisitions, licensing deals, and strategic partnerships. For pharmaceutical companies, understanding the scientific foundation and regulatory standing of a product or company is essential for mitigating risk and maximizing value.
This article explores the key components of scientific and regulatory due diligence and what pharma stakeholders need to consider at every stage.
What Is Scientific and Regulatory Due Diligence?
Scientific and regulatory due diligence involves a thorough evaluation of a product’s research data, clinical trial outcomes, intellectual property, regulatory filings, and compliance history. It is typically conducted prior to major business decisions, such as acquisitions, partnerships, or licensing agreements.
Unlike financial due diligence, which focuses on balance sheets and cash flow, scientific and regulatory due diligence delves into whether the product works, how it works, and whether it meets regulatory requirements across different markets.
Why It Matters
Inaccurate or incomplete scientific and regulatory assessments can lead to costly mistakes. For instance, a promising compound might show efficacy in early trials but lack sufficient safety data or suffer from manufacturing issues. Similarly, a company might claim to be regulatory-compliant but have unresolved warning letters or noncompliance with GMP (Good Manufacturing Practices).
Due diligence helps prevent surprises after a deal closes, ensuring stakeholders have a clear understanding of the risks, gaps, and opportunities.
Key Areas of Focus
1. Scientific Rationale and Data Integrity
The cornerstone of scientific due diligence is the evaluation of preclinical and clinical data. This includes assessing the robustness of the science, the reproducibility of results, and the design of clinical trials.
Due diligence teams should ask:
-
Are the studies designed appropriately and statistically powered?
-
Are the endpoints clinically relevant?
-
Has data been peer-reviewed or published in reputable journals?
-
Are the raw datasets available for independent analysis?
Reviewing raw data and protocols can uncover issues such as data manipulation, missing values, or flawed study designs that could impact the credibility of the results.
2. Regulatory Status and History
Understanding a product’s regulatory journey is critical. This includes:
-
Investigational New Drug (IND) applications
-
New Drug Applications (NDA) or Biologics License Applications (BLA)
-
Marketing authorizations from EMA, FDA, MHRA, and others
-
Orphan drug designations
-
Fast-track or breakthrough therapy designations
Equally important is reviewing correspondence with regulatory bodies. Letters from the FDA (such as Form 483s or Complete Response Letters) can reveal deeper issues with manufacturing, safety, or trial conduct.
A product like ELIQUENT, for example, would have gone through rigorous regulatory scrutiny before achieving market approval. Understanding the path such a product took can offer insights into the hurdles and milestones required for similar compounds.
3. Intellectual Property (IP)
The value of a pharmaceutical asset is heavily influenced by the strength and duration of its patent protection. IP due diligence involves:
-
Reviewing patent portfolios (composition, method of use, formulation)
-
Validity and enforceability of claims
-
Freedom to operate (FTO) assessments
-
Pending litigation or opposition proceedings
Weak or expiring IP protection can drastically reduce the commercial viability of a drug, even if it’s scientifically and clinically effective.
4. CMC and Manufacturing Compliance
Chemistry, Manufacturing, and Controls (CMC) is often an overlooked aspect of due diligence. However, poor manufacturing practices or an unreliable supply chain can halt product launch or lead to recalls.
Due diligence teams should assess:
-
GMP compliance of manufacturing facilities
-
Scalability of the manufacturing process
-
Stability and shelf-life data
-
Supply chain integrity and risks
5. Market and Competitive Landscape
While this strays into commercial due diligence, understanding the broader landscape can help put scientific and regulatory findings into context. Is the product differentiated? Are there competing therapies at a similar development stage? What’s the likelihood of market access and reimbursement?
Best Practices for Conducting Due Diligence
-
Assemble a cross-functional team: Include regulatory affairs professionals, clinical scientists, legal experts, and commercial analysts.
-
Use a structured checklist: Ensure no area is overlooked, from preclinical data to post-market commitments.
-
Engage external consultants when needed: Independent third parties can provide unbiased assessments, especially in complex or high-stakes deals.
-
Document findings clearly: Decision-makers should receive a well-organized report outlining risks, red flags, and recommended actions.
Final Thoughts
Scientific and regulatory due diligence is a cornerstone of informed decision-making in the pharmaceutical industry. With increasing complexity in drug development and global regulation, pharma companies cannot afford to cut corners. A diligent approach ensures that products like ELIQUENT—developed through years of research and regulatory navigation—are not only scientifically sound but also commercially viable.
As competition intensifies and regulatory scrutiny increases, pharma organizations must prioritize thorough, multidisciplinary due diligence to protect investments, accelerate development, and ultimately bring safe and effective therapies to market.
